Estimated five-year cumulative incidence of local recurrence 3.1 percent for women undergoing BCT and adjuvant radiation<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, April 12, 2023 (HealthDay News) — For women with multiple ipsilateral breast cancer, breast-conserving therapy (BCT) with adjuvant radiation results in a low five-year local recurrence rate, according to a study published online March 28 in the Journal of Clinical Oncology<\/em>.<\/p>\n Judy C. Boughey, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined oncologic outcomes in women aged 40 years and older with two to three foci of biopsy-proven cN0-1 breast cancer undergoing BCT. Participants underwent lumpectomy with negative margins, which was followed by whole-breast irradiation with a boost to all lumpectomy beds. A total of 204 eligible patients (median age, 61 years) underwent protocol-directed BCT.<\/p>\n The researchers found that six patients developed local recurrence at a median follow-up of 66.4 months, for an estimated five-year cumulative incidence of local recurrence of 3.1 percent. No associations were seen for patient age, number of sites of preoperative biopsy-proven breast cancer, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories with the risk for local recurrence. In an exploratory analysis, the five-year local recurrence rate was 22.6 and 1.7 percent, respectively, in patients without and with preoperative magnetic resonance imaging.<\/p>\n “This broadening of indications for BCT greatly benefits this growing population of patients as breast conservation is associated with better patient satisfaction and potentially improved survival,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical and medical technology industries; one author has a study-related patent pending.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n